We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Medifast's Q1 Earnings on The Horizon: Key Insights for Investors
Read MoreHide Full Article
Key Takeaways
MED posts Q1 fiscal 2026 results May 4 after close, with revenue consensus at $73.8M.
MED's sales likely stayed weak as active earning coaches fell and client acquisition remained challenged.
MED reduced marketing and restructured, but lower revenue, deleverage and R&D may slow margins.
As Medifast, Inc. (MED - Free Report) prepares to unveil its first-quarter fiscal 2026 earnings on May 04, after market close, investors are eager to see if the company can beat market expectations.
The Zacks Consensus Estimate for revenues is pegged at $73.8 billion, implying a 36.3% decline from the prior year. Meanwhile, the consensus mark for earnings has been unchanged at a loss of 55 cents per share in the past seven days, though it indicates a decline of 400% from the year-ago period’s actual. MED has a trailing four-quarter negative earnings surprise of 676.5%, on average.
Medifast’s top line is likely to have remained under pressure due to continued weakness in its active coach base. Declines in active earning coaches have been a primary driver of revenue contraction, alongside ongoing challenges in client acquisition. The operating environment remains difficult, reflecting broader disruption in the weight-loss category, including the rapid adoption of GLP-1 medications and shifting consumer expectations, which continue to weigh on demand for traditional programs.
The company’s ongoing transition toward a broader metabolic health platform may also have contributed to near-term headwinds. While this strategic repositioning expands Medifast’s long-term opportunity, improvements in underlying metrics have not yet translated into a meaningful impact on revenues. The shift in messaging and program focus requires time to gain traction with both coaches and clients, which likely continued to weigh on sales momentum during the quarter.
Bottom-line performance is also expected to have remained under pressure due to the combined effect of lower revenues and operating deleverage. Although Medifast has taken steps to align its cost structure with current demand, including reducing marketing spending and implementing restructuring actions, these measures may not fully offset the impact of weaker sales volumes. In addition, ongoing efforts to support its strategic transformation, including research and product development initiatives, may have limited the pace of margin recovery.
On the positive side, improving coach productivity could have provided some support to performance. At its last earnings call, management highlighted early signs of higher productivity within a more focused coach network, driven in part by the exit of less productive coaches and increased engagement in coach-led activities. While these improvements may not yet be sufficient to drive revenue growth, they suggest some stabilization in underlying trends.
What the Zacks Model Says About MED
Our proven model does not conclusively predict an earnings beat for MED this time. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat, which is not the case here.
MED has an Earnings ESP of 0.00% and a Zacks Rank #3. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
Stocks With Favorable Combination
Here are three companies you may also want to consider, as our model shows that these have the right combination of elements to post an earnings beat this season:
The Kraft Heinz Company (KHC - Free Report) currently has an Earnings ESP of +3.08% and a Zacks Rank of 3. The Zacks Consensus Estimate for first-quarter 2026 earnings per share is pegged at 50 cents, implying a 19.4% year-over-year decline. You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for quarterly revenues is pegged at $5.9 billion, which indicates a decrease of 1.5% from the figure reported in the prior-year quarter. KHC has a trailing four-quarter earnings surprise of 7%, on average.
Celsius Holdings, Inc. (CELH - Free Report) currently has an Earnings ESP of +3.81% and a Zacks Rank of 3. The Zacks Consensus Estimate for first-quarter fiscal 2026 earnings per share is pegged at 29 cents, implying a 61.1% year-over-year surge.
The Zacks Consensus Estimate for quarterly revenues is pegged at $755.2 million, which indicates an increase of 129.4% from the figure reported in the prior-year quarter. CELH has a trailing four-quarter earnings surprise of 45.3%, on average.
Freshpet, Inc. (FRPT - Free Report) currently has an Earnings ESP of +25.37% and a Zacks Rank of 3. The Zacks Consensus Estimate for first-quarter fiscal 2027 earnings per share is pegged at 6 cents, implying a 33.3% year-over-year decline.
The Zacks Consensus Estimate for quarterly revenues is pegged at $291 million, which indicates growth of 10.6% from the figure reported in the prior-year quarter. FRPT has a trailing four-quarter earnings surprise of 50%, on average.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Medifast's Q1 Earnings on The Horizon: Key Insights for Investors
Key Takeaways
As Medifast, Inc. (MED - Free Report) prepares to unveil its first-quarter fiscal 2026 earnings on May 04, after market close, investors are eager to see if the company can beat market expectations.
The Zacks Consensus Estimate for revenues is pegged at $73.8 billion, implying a 36.3% decline from the prior year. Meanwhile, the consensus mark for earnings has been unchanged at a loss of 55 cents per share in the past seven days, though it indicates a decline of 400% from the year-ago period’s actual. MED has a trailing four-quarter negative earnings surprise of 676.5%, on average.
MEDIFAST INC Price, Consensus and EPS Surprise
MEDIFAST INC price-consensus-eps-surprise-chart | MEDIFAST INC Quote
Key Factors to Note for MED's Q1 Earnings
Medifast’s top line is likely to have remained under pressure due to continued weakness in its active coach base. Declines in active earning coaches have been a primary driver of revenue contraction, alongside ongoing challenges in client acquisition. The operating environment remains difficult, reflecting broader disruption in the weight-loss category, including the rapid adoption of GLP-1 medications and shifting consumer expectations, which continue to weigh on demand for traditional programs.
The company’s ongoing transition toward a broader metabolic health platform may also have contributed to near-term headwinds. While this strategic repositioning expands Medifast’s long-term opportunity, improvements in underlying metrics have not yet translated into a meaningful impact on revenues. The shift in messaging and program focus requires time to gain traction with both coaches and clients, which likely continued to weigh on sales momentum during the quarter.
Bottom-line performance is also expected to have remained under pressure due to the combined effect of lower revenues and operating deleverage. Although Medifast has taken steps to align its cost structure with current demand, including reducing marketing spending and implementing restructuring actions, these measures may not fully offset the impact of weaker sales volumes. In addition, ongoing efforts to support its strategic transformation, including research and product development initiatives, may have limited the pace of margin recovery.
On the positive side, improving coach productivity could have provided some support to performance. At its last earnings call, management highlighted early signs of higher productivity within a more focused coach network, driven in part by the exit of less productive coaches and increased engagement in coach-led activities. While these improvements may not yet be sufficient to drive revenue growth, they suggest some stabilization in underlying trends.
What the Zacks Model Says About MED
Our proven model does not conclusively predict an earnings beat for MED this time. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat, which is not the case here.
MED has an Earnings ESP of 0.00% and a Zacks Rank #3. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
Stocks With Favorable Combination
Here are three companies you may also want to consider, as our model shows that these have the right combination of elements to post an earnings beat this season:
The Kraft Heinz Company (KHC - Free Report) currently has an Earnings ESP of +3.08% and a Zacks Rank of 3. The Zacks Consensus Estimate for first-quarter 2026 earnings per share is pegged at 50 cents, implying a 19.4% year-over-year decline. You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for quarterly revenues is pegged at $5.9 billion, which indicates a decrease of 1.5% from the figure reported in the prior-year quarter. KHC has a trailing four-quarter earnings surprise of 7%, on average.
Celsius Holdings, Inc. (CELH - Free Report) currently has an Earnings ESP of +3.81% and a Zacks Rank of 3. The Zacks Consensus Estimate for first-quarter fiscal 2026 earnings per share is pegged at 29 cents, implying a 61.1% year-over-year surge.
The Zacks Consensus Estimate for quarterly revenues is pegged at $755.2 million, which indicates an increase of 129.4% from the figure reported in the prior-year quarter. CELH has a trailing four-quarter earnings surprise of 45.3%, on average.
Freshpet, Inc. (FRPT - Free Report) currently has an Earnings ESP of +25.37% and a Zacks Rank of 3. The Zacks Consensus Estimate for first-quarter fiscal 2027 earnings per share is pegged at 6 cents, implying a 33.3% year-over-year decline.
The Zacks Consensus Estimate for quarterly revenues is pegged at $291 million, which indicates growth of 10.6% from the figure reported in the prior-year quarter. FRPT has a trailing four-quarter earnings surprise of 50%, on average.